STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis (STARS)
STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis (STARS Trial)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Scott K Heysell, MD, MPH
- Phone Number: 6962 434-924-0000
- Email: SKH8R@uvahealth.org
Study Contact Backup
- Name: Christopher C Moore, MD
- Phone Number: 3489 434-924-0000
- Email: ccm5u@uvahealth.org
Study Locations
-
-
-
Mwanza, Tanzania
- Sekou Toure Regional Referral Hospital
-
Contact:
- Frederick C Mwita, MD
- Phone Number: +255282502171
- Email: Cyprianfredy@gmail.com
-
Principal Investigator:
- Frederick C Mwita, MD
-
Sanya Juu, Tanzania
- Kibong'oto Infectious Diseases Hospital
-
Contact:
- Stellah G Kibong'oto, MD, PhD
- Phone Number: +255272974140
- Email: sempagama@yahoo.com
-
Contact:
- Bibie Said, MD
- Phone Number: +255272974140
- Email: bibiesd90@gmail.com
-
Principal Investigator:
- Stellah G Mpagama, MD, PhD
-
-
-
-
-
Fort Portal, Uganda
- Fort Portal Regional Referral Hospital
-
Contact:
- Dalton K Munyambalu, MBChB, MMed
- Phone Number: +256 717 555139
- Email: daltonkamuda@gmail.com
-
Principal Investigator:
- Dalton K Munyambalu, MBChB, MMed
-
Mbarara, Uganda
- Mbarara Regional Referral Hospital
-
Contact:
- Edwin Nuwagira, MBChB, MMed
- Phone Number: +256485420030
- Email: enuwagira@must.ac.ug
-
Principal Investigator:
- Edwin Nuwagira, MBChB, MMed
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female aged ≥18 years living with HIV
- Admitted to hospital with 1) clinical concern for infection; 2) ≥2 qSOFA score criteria (Glasgow Coma Scale score <15, a respiratory rate ≥22, or a systolic blood pressure ≤90 mmHg or a mean arterial pressure of ≤65 mmHg)
- Resident within a pre-defined geographic area to ensure TB clinic follow-up
- For females of reproductive potential: use of highly effective contraception through 28 days
Exclusion Criteria:
- Known active TB or receiving anti-TB therapy
- Pregnancy or lactation. Women will undergo urine pregnancy screening. Pregnant people will be excluded due to lack of pharmacokinetic data for the expanded antibiotic regimen in pregnancy.
- Known allergic reactions to the components of the interventional therapy
- Treatment with another investigational drug or other intervention within one month
- Known liver disease
- Alcohol use > 14 standardized drinks per week and/or > 4 drinks per day for men and >7 standardized drinks per week and/or >3 drinks per day for women, defined as 14 grams of ethanol, as found in example 5 ounces of wine, 12 ounces of beer, or 1.5 ounces of 80 proof spirits
- Positive serum cryptococcal antigen test
- Current treatment with a drug known to have significant, non-correctable interaction with anti-TB therapy
- Already receiving corticosteroids at the time of presentation to the hospital
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: No hydrocortisone/enhanced spectrum antimicrobial therapy
|
empiric initiation of the enhanced spectrum antimicrobial therapy regimen (rifampin, isoniazid, linezolid, and levofloxacin) for 14 days plus standard care which includes ceftriaxone for 7 days or diagnosis dependent conventional anti-TB therapy
|
|
Experimental: Hydrocortisone/enhanced spectrum antimicrobial therapy
|
Immediate hydrocortisone at 200 mg IV daily for 7 days and a tapering schedule for an additional 7 days
empiric initiation of the enhanced spectrum antimicrobial therapy regimen (rifampin, isoniazid, linezolid, and levofloxacin) for 14 days plus standard care which includes ceftriaxone for 7 days or diagnosis dependent conventional anti-TB therapy
|
|
No Intervention: No hydrocortisone/immediate anti-TB therapy
Standard of care
|
|
|
Experimental: Hydrocortisone/immediate anti-TB therapy
|
Immediate hydrocortisone at 200 mg IV daily for 7 days and a tapering schedule for an additional 7 days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mortality
Time Frame: 28 days from date of randomization
|
Primary outcome measure
|
28 days from date of randomization
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
In-hospital mortality
Time Frame: from enrollment through hospitalization, an average of 14 days
|
Mortality
|
from enrollment through hospitalization, an average of 14 days
|
|
6-month mortality
Time Frame: From the date of randomization until death or 180 days from randomization
|
Mortality
|
From the date of randomization until death or 180 days from randomization
|
|
Time to death
Time Frame: From date of randomization to death or 180 days from randomization
|
Mortality
|
From date of randomization to death or 180 days from randomization
|
|
Incidence of new post-admission shock
Time Frame: From the time of enrollment through hospital discharge, an average of 14 days
|
New post-admission shock
|
From the time of enrollment through hospital discharge, an average of 14 days
|
|
Duration of hospitalization
Time Frame: From the time of randomization until date of hospital discharge up to 180 days, or death if before hospital discharge
|
Duration of hospitalization
|
From the time of randomization until date of hospital discharge up to 180 days, or death if before hospital discharge
|
|
Volume of IV fluids received
Time Frame: From the date of randomization until date of hospital discharge up to 180 days, or date of death if occurring before discharge
|
Volume of IV fluids received
|
From the date of randomization until date of hospital discharge up to 180 days, or date of death if occurring before discharge
|
|
Adverse drug events during the 28-day study period
Time Frame: From date of randomization to 28 days post randomization or date of death if death occurred before 28 days
|
Adverse drug events
|
From date of randomization to 28 days post randomization or date of death if death occurred before 28 days
|
|
Time to ambulation
Time Frame: From date of randomization until the date of first documented ambulation during hospitalization, or date of death from any cause, whichever came first, on average over 14 days, but up to 180 days
|
Time to ambulation
|
From date of randomization until the date of first documented ambulation during hospitalization, or date of death from any cause, whichever came first, on average over 14 days, but up to 180 days
|
|
Time to temperature normalization
Time Frame: From date of randomization until the date of first documented normal temperature during hospitalization, or date of death from any cause, whichever came first, on average over 14 days, but up to 180 days
|
Time to temperature normalization
|
From date of randomization until the date of first documented normal temperature during hospitalization, or date of death from any cause, whichever came first, on average over 14 days, but up to 180 days
|
|
Lactate/delta lactate
Time Frame: From the date of randomization until the date of hospital discharge or the date of death if death occurred before discharge, on average 14 days
|
Lactate concentration change
|
From the date of randomization until the date of hospital discharge or the date of death if death occurred before discharge, on average 14 days
|
|
Capillary fill time/delta capillary fill time
Time Frame: From the date of randomization until the date of hospital discharge or the date of death if death occurred before discharge, on average 14 days
|
Change in capillary fill time
|
From the date of randomization until the date of hospital discharge or the date of death if death occurred before discharge, on average 14 days
|
|
Universal Vital Assessment score and delta Universal Vital Assessment score: component number one, heart rate
Time Frame: From the time of randomization to 72 hours after randomization
|
Calculation of initial Universal Vital Assessment mortality risk score at randomization and 72 hours after randomization: component number one, measure heart rate
|
From the time of randomization to 72 hours after randomization
|
|
Universal Vital Assessment mortality risk score at randomization and 72 hours after randomization: component number two, respiratory rate
Time Frame: From time to randomization to 72 hours
|
Calculation of initial Universal Vital Assessment mortality risk score at randomization and 72 hours after randomization: component number two, measure respiratory rate
|
From time to randomization to 72 hours
|
|
Calculation of initial Universal Vital Assessment mortality risk score at randomization and 72 hours after randomization: component number three, systolic blood pressure
Time Frame: From time to randomization to 72 hours
|
Calculation of initial Universal Vital Assessment mortality risk score at randomization and 72 hours after randomization: component number three, measure systolic blood pressure
|
From time to randomization to 72 hours
|
|
Calculation of initial Universal Vital Assessment mortality risk score at randomization and 72 hours after randomization: component number four, oxygen saturation
Time Frame: From time to randomization to 72 hours
|
Calculation of initial Universal Vital Assessment mortality risk score at randomization and 72 hours after randomization: component number four, measure oxygen saturation
|
From time to randomization to 72 hours
|
|
Calculation of initial Universal Vital Assessment mortality risk score at randomization and 72 hours after randomization: component number five, glascow coma scale
Time Frame: From time to randomization to 72 hours
|
Calculation of initial Universal Vital Assessment mortality risk score at randomization and 72 hours after randomization: component number five, record record level of consciousness by glascow come scale
|
From time to randomization to 72 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Scott K Heysell, MD, MPH, University of Virginia
- Principal Investigator: Christopher C Moore, MD, University of Virginia
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HSR302304
- 1U01AI192033-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.